18F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly.

MLA

Bakker, Leontine E. H., et al. “18F‐fluoro‐ethyl‐tyrosine PET Co‐registered with MRI in Patients with Persisting Acromegaly.” Clinical Endocrinology, vol. 101, no. 2, Aug. 2024, pp. 142–52. EBSCOhost, https://doi.org/10.1111/cen.15079.

APA

Bakker, L. E. H., Verstegen, M. J. T., Manole, D. C., Lu, H., Decramer, T. J. M., Pelsma, I. C. M., Kruit, M. C., Verbist, B. M., van de Ven, A., Gurnell, M., Ghariq, I., van Furth, W. R., Biermasz, N. R., & Pereira Arias, B. L. M. (2024). 18F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly. Clinical Endocrinology, 101(2), 142–152. https://doi.org/10.1111/cen.15079

Chicago

Bakker, Leontine E. H., Marco J. T. Verstegen, Diandra C. Manole, Huangling Lu, Thomas J. M. Decramer, Iris C. M. Pelsma, Mark C. Kruit, et al. 2024. “18F‐fluoro‐ethyl‐tyrosine PET Co‐registered with MRI in Patients with Persisting Acromegaly.” Clinical Endocrinology 101 (2): 142–52. doi:10.1111/cen.15079.